BMS Faces Antitrust Claims Over Delayed Generics for Cancer Drugs
A healthcare provider claims BMS paid rivals to postpone generic cancer drug launches, stoking antitrust scrutiny.
Why it matters: The case spotlights persistent legal tensions over pharmaceutical patent strategies and their impact on drug affordability. Any finding against BMS could shape future competition and pricing in the industry.
- BMS and Celgene allegedly paid competitors to delay generic Thalomid and Revlimid until at least January 2026.
- A healthcare provider accuses BMS of overcharging by keeping generics off the market.
- BMS settled with Dr. Reddy's Labs, allowing some generic Revlimid sales after March 2022, with full access in 2026.
- Revlimid revenues dropped 63% in early 2026 as generics entered the U.S. market.
Bristol Myers Squibb (BMS) and its subsidiary, Celgene, are under fire for allegedly orchestrating so-called "pay-for-delay" agreements that postponed lower-priced generics of two blockbuster cancer drugs—Thalomid and Revlimid. A healthcare provider has filed antitrust claims, asserting BMS overcharged by compensating generic manufacturers to withhold market entry until January 2026 or later, thereby limiting access and maintaining high prices. Recent reporting details ongoing concern about the role of settlements and licensing in keeping drug costs elevated for patients and payers.
- Notably, BMS settled U.S. patent disputes with Dr. Reddy's Laboratories in September 2020. Under that deal, Dr. Reddy's could begin selling volume-limited generic lenalidomide (Revlimid) after March 2022, but unrestricted sales could not begin until January 31, 2026, as announced in BMS's settlement statement.
- Industry observers view these arrangements as significant flashpoints within antitrust law. Critics say they delay generic access to essential medicines, while companies cite patent rights and litigation settlements as central to pharmaceutical innovation.
- The economic impact is already clear: BMS reported a 63% fall in Revlimid revenues for Q1 2026 due to diminished U.S. demand following the arrival of generics (SEC filing).
While the most recent class action—focused on BMS and Celgene's conduct around the drug Pomalyst—was dismissed by a U.S. District Judge in March 2025, the current pay-for-delay allegations over Thalomid and Revlimid keep the company's practices in the legal spotlight (dismissal report). The outcome of these new claims remains undetermined, but the case highlights how antitrust enforcement continues to challenge the balancing act between patent protection and access to affordable medication.
By the numbers:
- 63% — Revlimid revenues decreased in Q1 2026 after generics launched
- 2026 — Dr. Reddy's allowed unrestricted U.S. sales of generic Revlimid starting January 31
Yes, but: Details of the alleged pay-for-delay deals remain undisclosed, and the outcome of the new lawsuit is unresolved.
What's next: Legal proceedings over the latest pay-for-delay charges are ongoing; potential trial or settlement timelines are yet to be published.